A statement released earlier today by Goldman Sachs Group Inc. about Bayer (ETR:BAYN) raises the target price to 129.00EUR
- Updated: September 15, 2016
In an issued report on 9/15/2016 Goldman Sachs Group Inc. upped the target price of Bayer (ETR:BAYN) from 0EUR to 129EUR indicating a possible upside of 0.41%.
On 8/29/2016, Citigroup Corp. released a statement about Bayer(ETR:BAYN) bumped the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.24%.
Displaying a price of 91.44EUR, Bayer (ETR:BAYN) traded 7.14% lower on the day. The last stock price close is up 1.82% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day average of 0.04EUR and 200-day average of 0.03EUR. Volume of trade was was up over the average, with 10,000 shares of BAYN changing hands over the typical 211 shares.
Bayer has a one-year low of 0.03EUR and a 52 week high of 0.04EUR and has a total market value of 0.0 EUR.
Brief Synopsis About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.